Reviva Pharmaceuticals Holdings, Inc. (RVPH)
Reviva Pharmaceuticals Holdings, Inc. is a biopharmaceutical company focused on developing and commercializing treatments for conditions with limited therapeutic options. Its research programs include brain and psychiatric disorders, respiratory diseases, inflammatory conditions, and cardiometabolic disorders. The company’s lead candidate is brilaroxazine (RP5063), which is being studied across several neuropsychiatric uses, including schizophrenia, bipolar disorder, major depressive disorder, attention-deficit/hyperactivity disorder, behavioral and psychotic symptoms associated with dementia and Alzheimer’s disease, and Parkinson’s disease psychosis. Reviva is also advancing respiratory programs in pulmonary arterial hypertension and idiopathic pulmonary fibrosis, while earlier-stage work includes psoriasis and RP1208 for depression and obesity. Founded in 2018, the company is headquartered in Cupertino, California, and its common stock trades on OTC Markets under the symbol RVPH.
Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Upcoming Dividend Ex-Date | Dividend Payment Date | Upcoming Dividend | Dividend Yield | Next Earnings Date | P/E Ratio | Price-to-Book Ratio | Price-to-Sales Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Payout Ratio | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
OTC-RVPH
|
$0.60
|
13.8% Upside
|
Fair
|
$17.50 3,208.1% Upside
|
—
|
Bargain
|
Fair
|
—
|
—
|
—
|
0.0%
|
August 17, 2026
|
-0.4x
|
0.4x
|
—
|
7.08 M
|
-14.879 M
|
3.2%
|
86.8%
|
-19.7
|
—
|
121.5%
|
